Daily Stock List
Searchlight Minerals Corp. (SRCH)
SmarTrend Newsletters reported earlier on Searchlight Minerals Corp. (SRCH), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
An exploration stage company, Searchlight Minerals Corp. engages in the acquisition and exploration of mineral properties and slag reprocessing projects. The Company is focusing on the acquisition and development of projects in the southwestern United States. It holds interests in the Clarkdale Slag Project and the Searchlight Gold Project. The Company’s shares trade on the OTC Markets’ OTCQB. Searchlight Minerals has its corporate office in Henderson, Nevada.
The Clarkdale Slag Project is in Clarkdale, Arizona. It is a reclamation project to recover precious and base metals from the reprocessing of slag produced from the smelting of copper ore mined at the United Verde Copper Mine in Jerome, Arizona. The Searchlight Gold Project involves exploration for precious metals on mining claims near Searchlight, Nevada. The Clarkdale Slag Project is the more advanced of two ongoing projects.
The Searchlight Gold Project is an early-stage gold exploration project on 3,200 acres situated approximately 50 miles south of Las Vegas, Nevada. To conserve its cash and resources, Searchlight Minerals has decided to postpone further exploration on its Searchlight Gold Project until the Company is better able to determine the feasibility of its Clarkdale Slag Project. Upon deciding to resume its exploration program, work on the project site will be limited to the scope within the Plan of Operations. To perform any additional drilling or mining on the project, Searchlight would need to submit a new application to the Bureau of Land Management (BLM) for approval before the start of any such additional activities.
In May, Searchlight Minerals announced significant technical achievements in gold and iron recovery at its Clarkdale Slag Project. The achievements include, but are not limited to, the determination of precise nature of the gold contained in the slag material; the addition of a high temperature pre-treatment step that aids in the recovery of the gold and provides a saleable iron by-product; and up to a 60 percent extraction of metallic gold from fire assay of ion exchange resin. The Company believes that the project is commercially viable, if repeatable, at current results, based on these achievements.
Searchlight Minerals Corp. (SRCH), closed Wednesday's trading session at $0.24, even for the day, on 90,222 volume with 16 trades. The average volume for the last 60 days is 34,219 and the stock's 52-week low/high is $0.151/$0.674.
Petro River Oil Corp. (PTRC)
Pumps and Dumps, PennyStockPlayers, The Stock Scout, PennyStockClub, Penny Stock Pros, PennyStocks24, and Pennybuster reported earlier on Petro River Oil Corp. (PTRC), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Petro River Oil Corp. is an independent exploration and production company headquartered in Houston, Texas. It concentrates on its oil properties in the Mississippi Lime play in eastern Kansas. The Mississippi Lime play covers approximately 17 million acres in Oklahoma and Kansas, compared to 10- to 15 million acres in the Bakken and 6 million in the Eagle Ford. Petro River Oil has an extensive inventory of low cost, high return development drilling opportunities. Founded in 2011, Petro River Oil lists on the OTC Bulletin Board.
Petro River Oil completed several related transactions through which it acquired control of Petro River Oil, LLC (Petro LLC) and Petro’s wholly-owned subsidiary Petro River Operating, LLC. Petro River Oil’s specific goals include increasing production through developing its acreage; increasing profitability margins through evaluating and optimizing its production, and executing its business plan to increase property values, reserves, and expanding its asset base. Furthermore, the Company has substantial acreage and oil reserves in Missouri. Petro River's extensive portfolio includes over 115,000 net acres of oil and gas assets in Kansas, Missouri and Kentucky.
Petro River Oil is focusing on developing its recently acquired Mississippi Lime acreage in Kansas and also its heavy oil properties in Missouri and Kentucky. Early reservoir projects in Kansas were focused on proving reserve potential into the Bourbon Arch geological region of the Mississippi Lime play. The production response from this region established migration and asset production potential. Additionally, Petro River Oil engaged an extensive geologic study of its leasehold position using over 26,000 producers and 40 acres of a proprietary 3D data set. The Company’s intention is to raise capital to drill several prospective reserve targets.
Petro LLC is an emerging oil and gas producer that controls a substantial acreage position in the Southeast Kansas region of the Mississippi Lime formation. Owing to the acquisition of Petro River Oil, the Company has added 115,000 gross/85,000 net acres to its Oil and Gas portfolio. This includes five producing oil and gas wells in which Petro owns a 50 percent Working Interest (WI) and a 40 percent Net Revenue Interest (NRI).
This has established a foremost presence in the Mississippi Lime play. This acreage is in addition to the Company's present Oil and Gas portfolio. Moreover, Petro River Oil also acquired over 60 square miles of proprietary 3D seismic data over prospective Mississippi Lime acreage in the same region. As part of this acquisition, WI’s in leases in which Petro River Oil already has a stake were acquired from Mega Partners I for approximately 15.5mm shares.
Last month, Petro River Oil announced that on May 30, 2014, it acquired a control position in Bandolier Energy LLC. Bandolier is a company established to acquire, in an all-cash transaction, all of the outstanding membership units of Spyglass Energy Group LLC. Spyglass is the owner of a 100 percent WI in the Pearsonia West Concession in Osage County, Oklahoma. Pearsonia encompasses the largest contiguous oil and gas acreage position in Northeastern Oklahoma (approximately 106,000 acres) with substantial original oil in place, stacked reservoirs, and exploratory and development opportunities that can be accessed via horizontal and vertical drilling.
Petro River Oil Corp. (PTRC), closed Wednesday's trading session at $0.072, up 10.77%, on 3,075,700 volume with 101 trades. The average volume for the last 60 days is 470,590 and the stock's 52-week low/high is $0.019/$0.495.
International Isotopes, Inc. (INIS)
SmallCapVoice reported previously on International Isotopes, Inc. (INIS), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
OTC Bulletin Board listed International Isotopes, Inc. manufactures a full spectrum of nuclear medicine calibration and reference standards, high purity fluoride gases, and an assortment of cobalt-60 products including teletherapy sources. Additionally, the Company provides a broad selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications. International Isotopes also provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients. The Company is based in Idaho Falls, Idaho.
Its business consists of different business segments. These include the Depleted Uranium De-Conversion and Fluorine Extraction Process (FEP) Project; Radiochemicals for Cancer Treatment; Nuclear Medicine Reference and Calibration Standards; Medical Teletherapy Products, AOS Series Type B (U) Transportation Containers, and Transportation Services.
International Isotopes has developed a unique process to convert depleted uranium tails (the by-product produced from the enrichment of uranium) to ultra-high purity, high value industrial fluoride products. Fluoride products are a vital raw material for microelectronics, fiber optic cable, thin film photovoltaics (solar cells) and many other manufacturing processes. The Company exclusively owns the patents for the fluorine extraction process. Its de-conversion process will convert the DUF6 by-product (or tails) from uranium enrichment operations into depleted uranium tetrafluoride (DUF4). International Isotopes will then use its patented FEP technology to extract fluorine from the DUF4 for use in the manufacture of specialty, high-value fluoride gases.
The Company is working to advance its planned environmentally friendly, green technology, uranium de-conversion and fluorine extraction processing facility in Lea County, approximately 15 miles west of Hobbs, New Mexico. The new facility will be on a 640-acre site. The Company believes this new commercial facility will provide an excellent commercial opportunity. International Isotopes holds patents that give it exclusive rights for the Fluorine Extraction Process (FEP). This process produces high value, high purity fluoride gasses in tandem with uranium de-conversion.
In October 2012, International Isotopes announced that it received a license from the U.S. Nuclear Regulatory Commission (NRC) to build a depleted uranium de-conversion and fluorine extraction processing facility. The license, which has a 40-year term, was signed October 2, 2012 by the NRC.
In April of this year, International Isotopes and RadQual LLC announced that they obtained approval from the United States Nuclear Regulatory Commission (NRC) for their new lightweight flood source. They made the new RadLite™ available to customers on April 1, 2014. This new product is 60 percent lighter and 60 percent thinner than the original flood source design. International Isotopes owns a 24.5 percent interest in RadQual. The Company has an exclusive manufacturing agreement with RadQual for the manufacturing of nuclear medicine products.
International Isotopes, Inc. (INIS), closed Wednesday's trading session at $0.048, even for the day. The average volume for the last 60 days is 32,533 and the stock's 52-week low/high is $0.0225/$0.1591.
BioLargo, Inc. (BLGO)
Tiny Gems, FeedBlitz and Penny Sleuth reported on BioLargo, Inc. (BLGO), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
BioLargo, Inc. delivers technology-based products, which help solve some of the world's most important problems that threaten water, food, agriculture, healthcare and energy. The Company’s subsidiary is BioLargo Water, Inc. BioLargo Water showcases the Advanced Oxidation Systems, including its AOS Filter. This is a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo has its headquarters in Santa Ana, California and the Company’s shares trade on the OTCQB.
The BioLargo® AOS Filter, its featured AOS Filter system, facilitates constant and scalable treatment with maximum efficiency utilizing GRAS components to convert contaminates to H2O and CO2. It destroys hard to get contaminates and disinfects quickly and completely. It is complementary with multiple filter systems. It extends the life of filtration systems, lowers corrosion, and conserves chemistry.
BioLargo also owns a 50 percent interest in the Isan System. This system was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. BioLargo’s subsidiary Odor-No-More, Inc. features award-winning products serving the pet, equine, and consumer markets. This includes the Nature's Best Solution® and Deodorall® brands. The subsidiary Clyra Medical Technologies, Inc. concentrates on advanced wound care management. Clyra Medical Technologies is preparing to make Food and Drug Administration (FDA) 510(k) applications this year.
This past April, BioLargo announced it was issued U.S. Patent No. 8,679,515 entitled, "Activated Carbon Associated with Alkaline or Alkali Iodide" by the United States Patent and Trademark Office (USPTO). This new patent provides protection for the Company’s BioLargo® AOS Filter, "Advanced Oxidation System" and covers methods for activating carbon with advanced iodine technology to promote rapid oxidation, which dismantles and eliminates contaminants in water. The AOS filter is now undergoing industrial scale pilot testing at the University of Alberta's Department of Engineering.
Last week, BioLargo announced it was issued two new patents by the USPTO further strengthening its growing patent portfolio and demonstrating multiple technical fields for application of its advanced iodine platform technology. U.S. Patent number 8,757,253 was issued on June 24, 2014 for the moderation of oil extraction waste environments. U.S. Patent number 8,734,559 was issued on May 27, 2014 for the moderation of animal waste environments.
BioLargo, Inc. (BLGO), closed Wednesday's trading session at $0.698, up 7.22%, on 66,549 volume with 25 trades. The average volume for the last 60 days is 57,384 and the stock's 52-week low/high is $0.035/$1.24.
Accelerize New Media, Inc. (ACLZ)
FeedBlitz reported previously on Accelerize New Media, Inc. (ACLZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Accelerize New Media, Inc. owns and operates CAKE Marketing. CAKE is a highly scalable Software-as-a-Service (SaaS) platform. It provides a total online tracking solution for advertisers. The platform is strong, reliable and intuitive. It has unique features designed to make managing data easier so users don’t need a digital translator to understand. Accelerize New Media lists on the OTC Bulletin Board. The Company has its corporate headquarters in Newport Beach, California.
The CAKE Marketing hosted software solution offers tracking, reporting, and distribution for online marketing campaigns. The software is patent-pending. User-friendly wizards and real-time reporting guide users through every step of managing and optimizing campaigns.
CAKE’s multi-channel, enterprise suite of tools makes it easy for marketers to collect massive volumes of rich click-forward data. These include conversion information, landing page data, as well as impression traffic for display campaigns. Through providing one place to track, manage, and optimize attribution data, CAKE enables its users with fundamental new ways to maximize value from digital media campaigns. This is while integrating with existing marketing technology investments.
Last month, CAKE announced the availability of CAKE Ecommerce Tracking and Attribution. This is a highly scalable solution. It provides online retailers and other ecommerce organizations with the most granular and complete 360-degree view of customer purchasing habits generated from merging ecommerce tracking with other online traffic sources. These sources include display, search, mobile, lead generation, affiliate, and others. With these insights, performance marketers are equipped with the intelligence to work smarter with high-value traffic sources through measuring campaign effectiveness in real-time.
Today, CAKE announced that GameHouse, a global leader in casual games, selected CAKE to power the GameHouse Affiliate Program. This marks GameHouse's shift to leveraging enterprise-level software for running its affiliate program internally, versus relying on service-based offerings. CAKE provides a SaaS-based solution for advertisers, publishers and networks to track and manage their digital spend in real-time.
Accelerize New Media, Inc. (ACLZ), closed Wednesday's trading session at $1.25, down 4.58%, on 28,135 volume with 43 trades. The average volume for the last 60 days is 14,472 and the stock's 52-week low/high is $0.715/$1.90.
Kallo, Inc. (KALO)
The QualityStocks Daily Newsletter would like to spotlight Kallo, Inc. (KALO). Today, Kallo, Inc. closed trading at $0.06, even for the day. The stock’s average daily volume over the past 60 days is 44,253, and its 52-week low/high is $0.017/$0.45.
Kallo, Inc. announced earlier in January of this year, plans for a new head office to be fully operational in the third quarter of 2014. Today the company was delighted to announce that they have completed their move to a 11,500 square foot Head Office in Markham, Ontario. Exemplifying Kallo's determination, planning and management abilities to meet aggressive deadlines, this timely HQ move comes at a time when the company is set to announce their next achievement in delivering a $200M, Kallo MobileCare and Kallo RuralCare project to the Republic of Guinea.
Kallo, Inc. (KALO) leverages a suite of technologies to improve the quality and efficiency of care in the $6.3 trillion global healthcare industry. Offering centralized, congruent solutions that attend healthcare and business issues, the company addresses the needs of hospitals, ministries of health, physicians, and other healthcare organizations.
As a result of an expanding and aging population, coupled with an increasing number of people suffering from chronic diseases and lifestyle related conditions, healthcare expenditures continue to grow. Kallo is focused on introducing new healthcare technology that helps contain costs, enable better methods to monitor/treat medical conditions, and increase the reach of healthcare providers to remote areas.
The tailored solutions offered by Kallo complement existing infrastructure, workflows, and processes, increasing both uptime and productivity. The company’s suite of products complies with international, national, and regional standards, and its stringent quality control ensures repeatable, process-driven delivery for maximum performance.
Kallo’s executives and directors bring rich and diverse industry knowledge. Collectively, the management team reflects the strength of the company’s global network and the diversity of its global culture. The team’s entrepreneurship, passion, experience, and knowledge of healthcare enables Kallo to continually deliver higher standards. Disclaimer
Kallo, Inc. Company Blog
Kallo, Inc. News:
Kallo Inc. Moves to New Global Head Office
Kallo Inc. New Business Developments
Kallo Inc. - Announces Appointment of Two Senior Managers
P2 Solar, Inc. (PTOS)
The QualityStocks Daily Newsletter would like to spotlight P2 Solar, Inc. (PTOS). Today, P2 Solar, Inc. closed trading at $0.04, up 3.63%, on 41,000 volume with 5 trades. The stock’s average daily volume over the past 60 days is 75,853, and its 52-week low/high is $0.0122/$0.0731.
P2 Solar, Inc. (PTOS) participates in the lucrative renewable energy market as a developer of solar photovoltaic (PV) power projects, focusing its initiatives on “sunbelt” areas where sunlight exposure is abundant; renewable energy policies are favorable; public and private sectors are actively seeking to incorporate solar PV into their electricity consumption profiles; and where governments offer attractive subsidies to motivate development.
Acknowledging rising demand for clean energy worldwide, solar PV power’s increasingly competitive edge over grid electricity, and commercial efforts to reduce reliance on greenhouse gas emitting fossil fuels, P2 Solar invests and channels its resources to benefit from these global trends.
The company’s growth strategy centers on management’s aggressive mandate to develop 150 MWp of electricity generating capacity in several phases over the next few years. To this accord, the company is focused on further development of its project portfolio, which currently consists of the Langley Rooftop Project in British Columbia; the Rajgarh Mini-hydro Project in Punjab, India; and the Tibba Mini-hydro Project, also located in Punjab India.
Backed by executive leadership with more than 60 years of combined experience, P2 Solar continues to develop and expand its current projects while opportunistically pursuing development opportunities in other regions with favorable solar energy regimes, including Eastern Europe and Canada. Disclaimer
P2 Solar, Inc. Company Blog
P2 Solar, Inc. News:
P2 Solar Signs a 35 year Power Purchase Agreement
P2 Solar Signs Implementation Agreement for Rajgarh Hydro Project
P2 Solar Receives Government Approval for Rajgarh Hydro Project
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.205, up 7.89%, on 1,300 volume with 2 trades. The stock’s average daily volume over the past 60 days is 11,837, and its 52-week low/high is $0.15/$1.00.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. Highlights Recent Media Coverage of MRSA
Zenosense, Inc. Provides Development Update
Zenosense, Inc. Extends License to Include Cancer Applications
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.64, even for the day, on 2,500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 5,409, and its 52-week low/high is $0.25/$0.89.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
VistaGen Joins HESI's Cardiac Safety Committee and Working Groups
VistaGen Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine
Armco Metals Holdings, Inc. (AMCO)
The QualityStocks Daily Newsletter would like to spotlight Armco Metals Holdings, Inc. (AMCO). Today, Armco Metals Holdings, Inc. closed trading at $0.23, off by 5.35%, on 539,183 volume with 263 trades. The stock’s average daily volume over the past 60 days is 466,767, and its 52-week low/high is $0.185/$0.58.
Armco Metals Holdings, Inc. (AMCO), since its founding 10 years ago, has worked tirelessly to create low-cost, high-quality solutions to meet steel industry demands and achieve its goal to become the largest scrap steel recycler in China. The company operates through five subsidiaries located in key regions throughout the country to source, import, process, and distribute quality, environmentally friendly recycled scrap steel, as well as metal and non-ferrous metal ore.
Subsidiaries Armco Metals International, Ltd., Armco (Lianyungang) Renewable Metals, Inc., Armet (Lianyungang) Holdings, Inc., Henan Armco & Metawise Trading Co., Ltd., Armco Metals (Shanghai) Holding, Ltd. support Armco Metal’s overarching corporate mission and operate to provide the country’s steel production industry with sustainable, responsible solutions to its material needs. Aligned with China’s green initiatives, Armco Metals and its subsidiaries are helping the government reach its scrap metal consumption goal of 20% by 2015.
Leveraging long-standing relationships with more than 10 international metal suppliers, more than 100 small- and medium-sized Chinese steel production companies, and some of the country’s large state-run foundries, Armco Metals benefits from a steady and dependable supply of demand for the company’s high-quality product known for excellent market values.
Armco Metals’ management team has established a unique approach to business and environment by providing responsible solutions based on environmentally friendly practices; reliable, cost-effective sourcing; and quality metal products. Backed by more than 10 years of industry experience, company executives have successfully positioned the company as credible, dependable partner for customers, suppliers, and investors within the steel production market. Disclaimer
Armco Metals Holdings, Inc. Company Blog
Armco Metals Holdings, Inc. News:
China's Ministry of Industry and Information Technology Approves Subsidiary
Armco Metals Holdings, Inc. Receives Government Approval to Import 20,000 Metric Tons of Restricted Materials Annually
Armco Metals Holdings, Inc. Receives $15 Million Credit Approval From a Chinese Commercial Bank
Today's Top 3
Jet-Life Penny Stocks
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Armco Metals Holdings, Inc. (AMCO) China's Ministry of Industry and Information Technology Approves Subsidiary
- Banjo & Matilda (BANJ) Reports Record Wholesale Sales For Its Fall/Winter Seasons
- Big Tree Group, Inc. (BIGG) Launches New Domestic Online Ecommerce Platform
- Consorteum Holdings, Inc. (CSRH) Signs Mobile Application Development Contract With Bet Butler Limited
- eCrypt Technologies, Inc. (ECRY) Partners with e-SignLive by Silanis to Offer Field-Proven E-Signature Security
- Great Plains Holdings, Inc. (GTPH) Completes Final Phase of Real Estate Asset Project Ahead of Schedule
- Infinite Group, Inc. (IMCI) Announces Exclusive Government Channel Partner Agreement for Content Management Tools
- Innocent, Inc. (INCT) Launches Advisory Council
- International Stem Cell Corp. (ISCO) Signs Agreement Including Certain Terms for a Definitive License Agreement With Rohto Pharmaceutical Co., Ltd. of Japan
- Kallo, Inc. (KALO) Announces Appointment of Two Senior Managers
- LD Holdings, Inc. (LDHL) Signs Joint Venture With Internet Marketing Consortium
- Mabwe Minerals Inc. (MBMI) Raptor Resources Holdings Issues Update on the Derbyshire Stone Quarry
- Mobile Lads Corp. (MOBO) Signs Letter of Intent for Xtreme Mobility Software Acquisition
- NutraNomics, Inc. (NNRX) Whole Food Based Vitamins and Supplements Available on Amazon.com
- P2 Solar, Inc. (PTOS) Signs a 35 year Power Purchase Agreement
- Pan Global Corp. (PGLO) Launches Development of Solar Ecommerce Marketplace for India
- Raptor Resources Holdings Inc. (RRHI) Issues Update on the Derbyshire Stone Quarry
- Start Scientific, Inc. (STSC) is “One to Watch”
- VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
- Well Power Inc. (WPWR) Information to be Available through S&P Capital IQ Corporation Records Program
- WordLogic Corp. (WLGC) Announces Development of iOS 8 Version of Award-Winning iKnowU Keyboard
- Zenosense, Inc. (ZENO) Highlights Recent Media Coverage of MRSA